There are several applications for BGS numbers for new mutant stocks. Some of them have been processed and given BGS numbers (Table 1, p.90; 91-99) and the descriptions are published in this issue. However, some others were not given BGS numbers and are pending publication in BGN, because of various reasons.
If the gene (s) of the new mutant (s) was found to be allelic to a known gene, BGS number(s) will not be given and the stock(s) is not required to be sent to the Stock Center in Fort Collins, Colorado, U. S. A. The researcher(s) who found the mutant(s) is asked to maintain the stock(s). Information on those stocks will be published in BGN as Research Notes or in section VII.
Other aspects on the preparation of a description of a genetic stock are:
1. A number of mutants have been studied and reported in BGN and other journals, yet the description has not been published in BGN. It is important to publish the description in BGN.
2. Revision of a description is also equally important. The author of the original description is asked to prepare a revised version or sometimes a corrected version of the description of genetic stock(s).